FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to compounds of formula
and
possessing the protein kinase inhibitor property, their pharmaceutically acceptable salts, solvates and hydrates, as well as to the use thereof and a based pharmaceutical composition. In general formula (1) X1 represents N, CRt 1; X2 represents N, CRt 2, X3 represents N, CRt 3, X4 represents N, CH and wherein X1, X2, X3 and X4 are independently specified; Rt 1 represents -H, halogen, -COOH, -CH3, -CH2CH3, -OH, -OCH3, -OCH2CH3, -CN, -CH3OH; Rt 2 represents -H, halogen, -CH3, -CH2CH3, -OH, -OCH3, -OCH2CH3, -CN, CH2OH, -NH2; Rt 3 represents -H, -S(O)rR4, halogen, -CN, -COOH, -CONH2, -COOCH3, -COOCH2CH3; the cycle A represents phenyl or a 6-member heteroaryl cycle, wherein heteroaryl contains 1-2 heteroatoms specified in N optionally substituted by 1-4 groups R'; the cycle B represents phenyl or a 5- or 6-member heteroaryl cycle, wherein heteroaryl contains 1-2 heteroatoms specified in N, S optionally substituted by 1-5 groups Rb; Ra and Rb are independently specified and represent -H, halogen, -CN, -R6, -OR4, -NR4R5, -C(O)YR4, -S(O)rR4, -SO2NR4R5, -NR4SO2NR4R5 wherein Y is independently specified and represents a chemical bond, -O-, -S-, -NR3-; L1 represents NR3C(O) or C(O)NR3; R3, R4 and R5 are independently specified and represent H, C1-C6-alkyl, and also the group NR4 R5 may represent a 5- or 6-member saturated or aromatic cycle; in each case R6 is independently specified and represents C1-C6-alkyl optionally substituted by C1-C6- alkyl or 5-6 merous heterocyclyl which may be substituted by C1-C6-alkyl; r is equal to 0; In general formula (II) Z represents CH; X, represents CRt 1; X2 represents CRt 2, X3 represents CRt 3 X4 represents CH and wherein X1, X2, X3 and X4 are independently specified; Rt 1 represents -H; Rt 2 represents -H, -F; Rt 3 represents -H, -F; the cycle A represents phenyl or 6-member heteroaryl cycle wherein heteroaryl contains 1-2 heteroatoms specified in N optionally substituted by 1-4 groups R3; the cycle B represents phenyl or a 5- or 6-member heteroaryl cycle wherein heteroaryl contains 1-2 heteroatoms specified in N, S optionally substituted by 1-5 groups Rb, Ra and Rb are independently specified and represent -H, halogen, -CN, -R6, -OR4, -NR4R5, -C(O)YR4, -S(O)rR4, -SO2NR4R5 wherein Y is independently specified and represents a chemical bond, -NR3-; L represents NR3C(O) or C(O)NR3; R4 and R5 are independently specified and represent H, C1-C6-alkyl, also the group NR4R3 may represent a 6-member saturated cycle; in each case R6 is independently specified and represents, C1-C6-alkyl optionally substituted by C1-C6-alkyl or 5-6 member heterocyclyl which may be substituted by C1-C6-alkyl; r is equal to 0; m is equal to 1; p is equal to 1.2.
EFFECT: preparing the compounds possessing the protein kinase inhibitor property.
16 cl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW COMPOUND STIMULATORS OF GROWTH HORMONE SECRETION | 2003 |
|
RU2382042C2 |
| SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | 2013 |
|
RU2681209C2 |
| SUBSTITUTED BICYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHOD OF INHIBITION | 1998 |
|
RU2204557C2 |
| PROTEIN PHOSPHATASE-1 INHIBITORS AND USING THEM | 2009 |
|
RU2527561C2 |
| CYCLOPENTA(D)PYRIMIDINES AS PROTEIN KINASE AKT INHIBITORS | 2007 |
|
RU2481336C2 |
| THERAPEUTICALLY ACTIVE TRIAZOLES AND USE THEREOF | 2007 |
|
RU2469042C2 |
| NEW 5,6-DIHYDROPYRIDINE-2-ON COMPOUNDS APPLICABLE AS THROMBIN INHIBITORS | 2004 |
|
RU2335492C2 |
| DIHYDROBENZODIAZEPINES, METHODS FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2000 |
|
RU2247115C2 |
| NEW FIVE-MEMBER HETEROCYCLES, THEIR PREPARING, THEIR APPLYING AND PHARMACEUTICAL PREPARATIONS COMPRISING THEREOF | 1998 |
|
RU2240326C2 |
| MONOMER DERIVATIVES OF GLYCOPEPTIDE ANTIBIOTIC | 2005 |
|
RU2424248C2 |
